Eithne M Costello

List of Publications by Year
in descending order

109 papers	7,758 citations	57758 44 h-index	53230 85 g-index
114 all docs	114 docs citations	114 times ranked	12668 citing authors

#	Article	IF	Citations
1	Therapeutic developments in pancreatic cancer: current and future perspectives. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 333-348.	17.8	762
2	Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology, 2011, 54, 1767-1776.	7.3	464
3	Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncology, The, 2014, 15, 829-840.	10.7	296
4	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nature Genetics, 2014, 46, 994-1000.	21.4	294
5	Early detection of pancreatic cancer. The Lancet Gastroenterology and Hepatology, 2020, 5, 698-710.	8.1	258
6	Biology and management of pancreatic cancer. Postgraduate Medical Journal, 2008, 84, 478-497.	1.8	254
7	Pancreatic Cancer hENT1 Expression and Survival From Gemcitabine in Patients From the ESPAC-3 Trial. Journal of the National Cancer Institute, 2014, 106, djt347.	6.3	231
8	Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma. JAMA Oncology, 2017, 3, 774.	7.1	221
9	GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut, 2017, 66, 1665-1676.	12.1	212
10	Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy. Molecular Cancer, 2011, 10, 37.	19.2	200
11	New biomarkers and targets in pancreatic cancer and their application to treatment. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 435-444.	17.8	194
12	Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. Clinical Cancer Research, 2015, 21, 2325-2337.	7.0	170
13	Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. Journal of Pathology, 2003, 201, 63-74.	4.5	166
14	Proteomic Analysis of Chronic Pancreatitis and Pancreatic Adenocarcinoma. Gastroenterology, 2005, 129, 1454-1463.	1.3	162
15	Identification of a Three-Biomarker Panel in Urine for Early Detection of Pancreatic Adenocarcinoma. Clinical Cancer Research, 2015, 21, 3512-3521.	7.0	161
16	Serum CA19-9 Is Significantly Upregulated up to 2 Years before Diagnosis with Pancreatic Cancer: Implications for Early Disease Detection. Clinical Cancer Research, 2015, 21, 622-631.	7.0	158
17	Application of laser capture microdissection combined with two-dimensional electrophoresis for the discovery of differentially regulated proteins in pancreatic ductal adenocarcinoma. Proteomics, 2003, 3, 1988-2001.	2.2	155
18	Analysis of gene expression in cancer cell lines identifies candidate markers for pancreatic tumorigenesis and metastasis. International Journal of Cancer, 2004, 112, 100-112.	5.1	155

#	Article	IF	Citations
19	Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Gastroenterology, 2018, 155, 1625-1639.e2.	1.3	152
20	High Nuclear S100A6 (Calcyclin) Is Significantly Associated with Poor Survival in Pancreatic Cancer Patients. Cancer Research, 2005, 65, 3218-3225.	0.9	123
21	Diagnosis of Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis by Measurement of microRNA Abundance in Blood and Tissue. PLoS ONE, 2012, 7, e34151.	2.5	106
22	Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice. Gastroenterology, 2016, 151, 1218-1231.	1.3	100
23	S100A6 binds to annexin 2 in pancreatic cancer cells and promotes pancreatic cancer cell motility. British Journal of Cancer, 2009, 101, 1145-1154.	6.4	92
24	High mobility group chromosomal protein 1 binds to the adeno-associated virus replication protein (Rep) and promotes Rep-mediated site-specific cleavage of DNA, ATPase activity and transcriptional repression. EMBO Journal, 1997, 16, 5943-5954.	7.8	91
25	Dual-color Proteomic Profiling of Complex Samples with a Microarray of 810 Cancer-related Antibodies. Molecular and Cellular Proteomics, 2010, 9, 1271-1280.	3.8	90
26	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget, 2016, 7, 66328-66343.	1.8	88
27	Proteomic analysis of pancreatic cancer stem cells: Functional role of fatty acid synthesis and mevalonate pathways. Journal of Proteomics, 2017, 150, 310-322.	2.4	87
28	Early Epigenetic Downregulation of microRNA-192 Expression Promotes Pancreatic Cancer Progression. Cancer Research, 2016, 76, 4149-4159.	0.9	77
29	Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. Clinical Cancer Research, 2016, 22, 1734-1743.	7.0	69
30	Activated Schwann cells in pancreatic cancer are linked to analgesia via suppression of spinal astroglia and microglia. Gut, 2016, 65, 1001-1014.	12.1	65
31	The role of inflammatory cells in fostering pancreatic cancer cell growth and invasion. Frontiers in Physiology, 2012, 3, 270.	2.8	64
32	Low molecular weight heat shock protein HSP27 is a prognostic indicator in rectal cancer but not colon cancer. Gut, 2010, 59, 1501-1510.	12.1	62
33	Multifunctional Fe3O4 nanoparticles for targeted bi-modal imaging of pancreatic cancer. Journal of Materials Chemistry, 2011, 21, 12650.	6.7	62
34	Secretome protein signature of human pancreatic cancer stem-like cells. Journal of Proteomics, 2016, 136, 1-12.	2.4	61
35	Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. Lancet Oncology, The, 2017, 18, 486-499.	10.7	60
36	iTRAQ reveals candidate pancreatic cancer serum biomarkers: influence of obstructive jaundice on their performance. British Journal of Cancer, 2013, 108, 1846-1853.	6.4	58

#	Article	IF	Citations
37	<scp>TERT</scp> gene harbors multiple variants associated with pancreatic cancer susceptibility. International Journal of Cancer, 2015, 137, 2175-2183.	5.1	57
38	Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Gut, 2017, 66, 314-322.	12.1	56
39	Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Molecular Cancer, 2014, 13, 114.	19.2	54
40	The expression of S100A8 in pancreatic cancer-associated monocytes is associated with the Smad4 status of pancreatic cancer cells. Proteomics, 2007, 7, 1929-1940.	2.2	51
41	Pancreatic Cancer Susceptibility Loci and Their Role in Survival. PLoS ONE, 2011, 6, e27921.	2.5	49
42	<scp>UHRF1</scp> regulation of the Keap1â€“Nrf2 pathway in pancreatic cancer contributes to oncogenesis. Journal of Pathology, 2016, 238, 423-433.	4.5	48
43	The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. British Journal of Cancer, 2016, 115, 887-894.	6.4	48
44	Somatic Mutations in Exocrine Pancreatic Tumors: Association with Patient Survival. PLoS ONE, 2013, 8, e60870.	2.5	47
45	Smad4 loss is associated with fewer S100A8-positive monocytes in colorectal tumors and attenuated response to S100A8 in colorectal and pancreatic cancer cells. Carcinogenesis, 2010, 31, 1541-1551.	2.8	46
46	Genetic susceptibility to pancreatic cancer and its functional characterisation: The PANcreatic Disease ReseArch (PANDoRA) consortium. Digestive and Liver Disease, 2013, 45, 95-99.	0.9	45
47	The unfolded protein response regulator GRP78 is a novel predictive biomarker in colorectal cancer. International Journal of Cancer, 2013, 133, 1408-1418.	5.1	45
48	A technically detailed and pragmatic protocol for quantitative serum proteomics using iTRAQ. Journal of Proteomics, 2009, 73, 352-356.	2.4	44
49	Confounding Effect of Obstructive Jaundice in the Interpretation of Proteomic Plasma Profiling Data for Pancreatic Cancer. Journal of Proteome Research, 2009, 8, 142-148.	3.7	44
50	cAMP inhibits migration, ruffling and paxillin accumulation in focal adhesions of pancreatic ductal adenocarcinoma cells: Effects of PKA and EPAC. Biochimica Et Biophysica Acta - Molecular Cell Research, 2013, 1833, 2664-2672.	4.1	44
51	New insights for early intervention and detection. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 71-73.	17.8	41
52	Functional single nucleotide polymorphisms within the cyclin-dependent kinase inhibitor 2A/2B region affect pancreatic cancer risk. Oncotarget, 2016, 7, 57011-57020.	1.8	41
53	The Nrf2 inhibitor brusatol is a potent antitumour agent in an orthotopic mouse model of colorectal cancer. Oncotarget, 2018, 9, 27104-27116.	1.8	40
54	Pancreatic Cancer Risk in Relation to Lifetime Smoking Patterns, Tobacco Type, and Doseâ€“Response Relationships. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1009-1018.	2.5	39

#	Article	IF	Citations
55	S100A8 and S100A9 proteins form part of a paracrine feedback loop between pancreatic cancer cells and monocytes. BMC Cancer, 2018, 18, 1255.	2.6	37
56	Biomarkers for early diagnosis of pancreatic cancer. Expert Review of Gastroenterology and Hepatology, 2015, 9, 305-315.	3.0	36
57	Deciphering the complex interplay between pancreatic cancer, diabetes mellitus subtypes and obesity/BMI through causal inference and mediation analyses. Gut, 2021, 70, gutjnl-2019-319990.	12.1	36
58	Stable Transduction with Lentiviral Vectors and Amplification of Immature Hematopoietic Progenitors from Cord Blood of Preterm Human Fetuses. Human Gene Therapy, 2001, 12, 377-389.	2.7	35
59	5â€Fluorouracil or gemcitabine combined with adenoviralâ€mediated reintroduction of p16^{INK4A} greatly enhanced cytotoxicity in Pancâ€1 pancreatic adenocarcinoma cells. Journal of Gene Medicine, 2004, 6, 514-525.	2.8	34
60	From mice to men: Murine models of colorectal cancer for use in translational research. Critical Reviews in Oncology/Hematology, 2016, 98, 94-105.	4.4	34
61	Current status of GV1001 and other telomerase vaccination strategies in the treatment of cancer. Expert Review of Vaccines, 2010, 9, 1007-1016.	4.4	33
62	A combination of urinary biomarker panel and PancRISK score for earlier detection of pancreatic cancer: A caseâ€“control study. PLoS Medicine, 2020, 17, e1003489.	8.4	33
63	Genetics and Prevention of Pancreatic Cancer. Cancer Control, 2004, 11, 6-14.	1.8	31
64	Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Journal of Medical Genetics, 2021, 58, 369-377.	3.2	31
65	Pancreatic Cancer: Proteomic Approaches to a Challenging Disease. Pancreatology, 2009, 9, 567-576.	1.1	30
66	Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. British Journal of Cancer, 2018, 118, 947-954.	6.4	30
67	New treatment options for advanced pancreatic cancer. Expert Review of Gastroenterology and Hepatology, 2008, 2, 673-696.	3.0	27
68	Designing a bio-inspired biomimetic in vitro system for the optimization of ex vivo studies of pancreatic cancer. Drug Discovery Today, 2017, 22, 690-701.	6.4	27
69	Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker. Oncotarget, 2018, 9, 32984-32996.	1.8	27
70	Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer. Annals of Surgery, 2018, 267, 364-369.	4.2	26
71	Choline Kinase Alpha (CHKÎ±) as a Therapeutic Target in Pancreatic Ductal Adenocarcinoma: Expression, Predictive Value, and Sensitivity to Inhibitors. Molecular Cancer Therapeutics, 2016, 15, 323-333.	4.1	25
72	Gene therapy for pancreatic cancerâ€”current and prospective strategies. Surgical Oncology, 2000, 9, 181-191.	1.6	23

#	Article	IF	Citations
73	A metabolomics-based biomarker signature discriminates pancreatic cancer from chronic pancreatitis. Gut, 2018, 67, 2-3.	12.1	22
74	Lack of Replication of Seven Pancreatic Cancer Susceptibility Loci Identified in Two Asian Populations. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 320-323.	2.5	20
75	Proteomic technologies and their application to pancreatic cancer. Expert Review of Proteomics, 2004, 1, 493-501.	3.0	19
76	The pancreatic cancer proteome â€“ recent advances and future promise. Proteomics - Clinical Applications, 2007, 1, 1066-1079.	1.6	19
77	Fibroblasts from Distinct Pancreatic Pathologies Exhibit Disease-Specific Properties. Cancer Research, 2020, 80, 2861-2873.	0.9	19
78	Tetracycline-inducible protein expression in pancreatic cancer cells: Effects of CapG overexpression. World Journal of Gastroenterology, 2011, 17, 1947.	3.3	18
79	Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. EBioMedicine, 2022, 75, 103802.	6.1	18
80	Immunobiological effects of gemcitabine and capecitabine combination chemotherapy in advanced pancreatic ductal adenocarcinoma. British Journal of Cancer, 2016, 114, 510-518.	6.4	17
81	A multilayered post-GWAS assessment on genetic susceptibility to pancreatic cancer. Genome Medicine, 2021, 13, 15.	8.2	15
82	miRNA dynamics in tumor-infiltrating myeloid cells modulating tumor progression in pancreatic cancer. OncoImmunology, 2016, 5, e1160181.	4.6	14
83	Pancreatic cancer and autoimmune diseases: An association sustained by computational and epidemiological caseâ€“control approaches. International Journal of Cancer, 2019, 144, 1540-1549.	5.1	11
84	Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer. International Journal of Cancer, 2018, 142, 1010-1021.	5.1	11
85	Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy. British Journal of Cancer, 2018, 118, 1084-1088.	6.4	9
86	Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. Carcinogenesis, 2019, 40, 544-550.	2.8	8
87	Recent advances in understanding pancreatic cancer. Faculty Reviews, 2022, 11, 9.	3.9	8
88	Nanotechnology advances in upper gastrointestinal, liver and pancreatic cancer. Expert Review of Gastroenterology and Hepatology, 2012, 6, 343-356.	3.0	7
89	F1F0-ATP Synthase Inhibitory Factor 1 in the Normal Pancreas and in Pancreatic Ductal Adenocarcinoma: Effects on Bioenergetics, Invasion and Proliferation. Frontiers in Physiology, 2018, 9, 833.	2.8	7
90	Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. JNCI Cancer Spectrum, 2020, 4, pkz060.	2.9	7

#	Article	IF	Citations
91	The holding temperature of blood during a delay to processing can affect serum and plasma protein measurements. Scientific Reports, 2021, 11, 6487.	3.3	7
92	Lack of Association for Reported Endocrine Pancreatic Cancer Risk Loci in the PANDoRA Consortium. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1349-1351.	2.5	5
93	hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Cancers, 2021, 13, 5758.	3.7	5
94	The role of microRNAs in the modulation of cancer-associated fibroblasts activity during pancreatic cancer pathogenesis. Journal of Physiology and Biochemistry, 2023, 79, 193-204.	3.0	5
95	Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 2342-2345.	2.5	4
96	Predictive cytokine biomarkers for survival in patients with advanced pancreatic cancer randomized to sequential chemoimmunotherapy comprising gemcitabine and capecitabine (GemCap) followed by the telomerase vaccine GV1001 compared to concurrent chemoimmunotherapy in the TeloVac phase III trial.. Journal of Clinical Oncology, 2014, 32, 4121-4121.	1.6	4
97	Genetics and Prevention of Pancreatic Cancer. Cancer Control, 2004, 11, 6-14.	1.8	4
98	Inclusion of cancer-associated fibroblasts in drug screening assays to evaluate pancreatic cancer resistance to therapeutic drugs. Journal of Physiology and Biochemistry, 2021, , 1.	3.0	3
99	Genetically Determined Telomere Length Is Associated with Pancreatic Neuroendocrine Neoplasms Onset. Neuroendocrinology, 2022, 112, 1168-1176.	2.5	3
100	Trials of gene therapy for pancreatic carcinoma. Current Gastroenterology Reports, 2005, 7, 165-169.	2.5	2
101	Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival. Scientific Reports, 2021, 11, 7570.	3.3	2
102	Pancreatic Mass in a Young CFTR Carrier With a Heterozygous p.R117H CFTR Gene Mutation and Homozygous 7T. Pancreas, 2015, 44, 343-345.	1.1	1
103	Development of Novel Diagnostic Pancreatic Tumor Biomarkers. , 2018, , 1241-1272.		1
104	Role of cytokines in the interplay between cancer cells and stroma-associated monocytes. BMC Genomics, 2014, 15, .	2.8	0
105	Principles and Applications of Proteomics in Pancreatic Cancer. , 2010, , 509-533.		0
106	Proteomic Analysis of Blood and Pancreatic Juice. , 2010, , 223-241.		0
107	Development of Novel Diagnostic Pancreatic Tumor Biomarkers 2nd ed. , 2017, , 1-32.		0
108	Challenges and Opportunities for Early Pancreatic Cancer Detection: Role for Protein Biomarkers. Molecular and Translational Medicine, 2020, , 73-82.	0.4	0

#	Article	IF	Citations
109	Molecular Biological Understanding of Development of Pancreatic Cancer. , 0, , 583-590.		0